Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Caribou Biosciences, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CRBU
Nasdaq
2830
cariboubio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Caribou Biosciences, Inc.
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
- Jan 13th, 2025 12:05 am
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
- Jan 7th, 2025 9:00 pm
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
- Jan 2nd, 2025 1:00 pm
Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In?
- Dec 30th, 2024 8:01 pm
Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely
- Dec 23rd, 2024 1:59 pm
Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Dec 16th, 2024 2:55 pm
Caribou Biosciences to Participate in Upcoming Investor Conferences
- Nov 20th, 2024 9:00 pm
Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
- Nov 10th, 2024 12:52 pm
Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 8th, 2024 11:22 am
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
- Nov 6th, 2024 11:05 pm
Caribou Biosciences Reports Third Quarter 2024 Financial Results andĀ Provides Business Update
- Nov 6th, 2024 9:05 pm
Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?
- Oct 31st, 2024 7:53 am
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
- Sep 25th, 2024 1:00 pm
With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing
- Sep 18th, 2024 11:34 am
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
- Sep 3rd, 2024 12:00 pm
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
- Aug 12th, 2024 12:00 pm
Caribou Biosciences Second Quarter 2024 Earnings: Beats Expectations
- Aug 8th, 2024 10:23 am
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
- Aug 6th, 2024 10:50 pm
Caribou Biosciences Reports Second Quarter 2024 Financial Results andĀ Provides Business Update
- Aug 6th, 2024 8:05 pm
Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Aug 6th, 2024 2:00 pm
Scroll